articleThe Lancet OncologyMar 23, 2017GREEN OA

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

Charité - Universitätsmedizin Berlin · Cornell University · +11 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

538
total citations
FWCI
20.41
Percentile
100%
References
37
Citations per year

Authors

15

Topics & keywords

Keywords
  • Medicine
  • Taxane
  • Trastuzumab
  • Trastuzumab emtansine
  • Clinical endpoint
  • Internal medicine
  • Regimen
  • Tolerability
No related works found for this paper.

Funding